Evoke Pharma, Inc. (NasdaqCM: EVOK)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Evoke Pharma, Inc. (NasdaqCM: EVOK) operates in the Pharmaceuticals industry within the Health Care sector.
trading between 4.23 and 11.00.
Tweenvest scores Evoke Pharma, Inc. across four factors: quality 29/100, value 52/100. Its strongest factor is value.
EVOK price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $14.42M
- P/E
- —
- EPS
- -1.88
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $11.00
- 52-week low
- $4.23
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 3
- Next earnings
- —
About Evoke Pharma, Inc.
Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials. This medicine is being developed to mitigate symptoms associated with both acute and recurring diabetic gastroparesis, specifically in female patients. Evoke Pharma distributes its offerings to a broad base of healthcare professionals, encompassing digestive disease specialists, internists, general practitioners, and certain other medical providers. Established in 2007, the company's corporate offices are situated in Solana Beach, California.
- ISIN
- US30049G3020
- Founded
- 2007
- Listed since
- Sep 25, 2013
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.